Biotechnology Events

Home

Axovant Sciences Ltd.

.

Development Update

Intepirdine, nelotanserin, RVT-103 and RVT-104 are being developed as potential treatments for patients with Alzheimer's disease and Lewy body dementia (LBD). The Company expects top-line results from the following late-stage clinical studies:

MINDSET: Phase 3 study of intepirdine in subjects with mild-to-moderate Alzheimer's disease on a stable background of donepezil therapy. Expected timing: last patient visit in August followed by results in late September 2017.

HEADWAY-DLB: Phase 2b study of intepirdine in subjects with dementia with Lewy bodies (DLB). Expected timing: fourth quarter 2017.

Phase 2 study of the effects of intepirdine on gait and balance in subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Expected timing: fourth quarter 2017.

Phase 2 study evaluating nelotanserin for treatment of subjects with LBD who experience frequent visual hallucinations. Expected timing: fourth quarter 2017.

Phase 2 study evaluating nelotanserin for treatment of REM Behavior Disorder in subjects with LBD. Expected timing: first quarter 2018.
More
Source: press release, 8/07/17. http://investors.axovant.com/news-releases/news-release-details/axovant-...

.

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Estimated Enrollment: 40
Study Start Date: October 2016
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
More
Source: clinical trials.gov. https://clinicaltrials.gov/ct2/show/NCT02910102?term=intepirdine&rank=3

.

Compound/DeviceSpecialtyIndicationCompound ClassTarget
Intepirdine (RVT-101) ADNeurologyAlzheimers Disease5-HT6 receptor antagonist5-HT6 receptor

Mechanism of action: Intepirdine (RVT-101) (SB-742457) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.

Phase of Development: II

Event Type: Data: Phase II trial results

Dates: 2017-10-01 - 2017-12-31

Results: Pending